Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin, André Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, W Wiktor-Jędrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate J. Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Chang, Darrin M. Beaupre, Lori Kunkel, Kristie A. Blum

New England Journal of Medicine, 2013

The University of Texas MD Anderson Cancer Center, Derriford Hospital, Cornell University, Hackensack University Medical Center, University of Wisconsin–Madison, Jagiellonian University, Stanford University, Stanford Medicine, University of Virginia, Long Island Jewish Medical Center, Centrum Onkologii, The Christie NHS Foundation Trust, University Hospital Ulm, LMU Klinikum, Medical University of Warsaw, Cancer Research UK, University of Southampton, Oregon Health & Science University, Radiation Oncology Associates, Baylor College of Medicine, Pharmacyclics (United States), The Ohio State University

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1671

Citations

View on Google Scholar

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Abstract

Journal Details

Join JournalsHub

Welcome Back